```html

Wegener’s Granulomatosis (Granulomatosis with Polyangiitis)

Overview

Granulomatosis with polyangiitis (GPA), historically known as Wegener’s granulomatosis, is a rare, autoimmune vasculitis that primarily attacks small‑ and medium‑sized blood vessels. The disease is characterized by necrotizing granulomatous inflammation of the respiratory tract and necrotizing vasculitis that can involve the kidneys, skin, eyes, nerves, and other organs.

• Prevalence: Approximately 3 – 4 cases per 100,000 adults in North America and Europe.
• Typical age of onset: 40–60 years, but pediatric cases occur.
• Sex distribution: Slight male predominance (about 55 % men).
• Geography: Occurs worldwide; incidence is slightly higher in Northern Europe and North America.

Because GPA can progress rapidly and affect vital organs, early recognition and treatment are crucial for survival. The 5‑year survival rate has improved from <10 % before the 1990s to >80 % with modern therapy (Mayo Clinic, 2022).

Symptoms

GPA often presents with a triad of respiratory, renal, and systemic features, but any organ system can be involved. Symptoms may appear abruptly or evolve over months.

Upper respiratory tract

• Chronic sinusitis or recurrent sinus infections
• Nasal crusting, ulceration, or perforation
• Persistent ear pain or hearing loss (due to eustachian tube dysfunction)
• Hoarseness or chronic cough

Lower respiratory tract

• Dry cough
• Hemoptysis (coughing up blood)
• Shortness of breath
• Chest pain, especially pleuritic
• Evidence of lung nodules, cavitary lesions, or infiltrates on imaging

Renal involvement

• Hematuria (blood in urine)
• Proteinuria
• Rapidly progressive glomerulonephritis leading to decreased urine output
• Elevated serum creatinine

Systemic / General

• Fever, night sweats
• Unexplained weight loss
• Fatigue and malaise
• Arthralgias or myalgias
• Skin lesions: palpable purpura, ulcerations, or livedo reticularis
• Eye inflammation (scleritis, uveitis)
• Peripheral neuropathy (mononeuritis multiplex)

Rare but reported manifestations

• Gastrointestinal bleeding
• Cardiac involvement (pericarditis, myocarditis)
• Hepatic or splenic granulomas

Causes and Risk Factors

The exact trigger for GPA remains unknown, but it is considered an autoimmune disease driven by antineutrophil cytoplasmic antibodies (ANCAs), particularly proteinase‑3 ANCA (PR3‑ANCA). Several factors appear to increase risk.

Potential mechanisms

• ANCA‑mediated neutrophil activation: ANCAs bind to PR3 or myeloperoxidase on neutrophils, causing degranulation and vessel wall injury.
• Genetic predisposition: Certain HLA‑DQ alleles (e.g., HLA‑DQβ1*0401) are over‑represented in patients.
• Environmental exposures: Silica dust, farming occupations, and certain infections (Staphylococcus aureus colonization of the nose) have been implicated in observational studies.

Identified risk factors

• Age 40–60 years (peak incidence)
• Male sex (modest increase)
• Northern European ancestry
• History of chronic nasal carriage of S. aureus
• Exposure to silica or other inorganic dusts

It is important to emphasize that having these risk factors does not mean a person will develop GPA, and many patients have no identifiable trigger.

Diagnosis

Diagnosing GPA requires a combination of clinical suspicion, laboratory testing, imaging, and often a tissue biopsy. No single test is definitive.

Laboratory studies

• ANCA testing:
  • PR3‑ANCA (c‑ANCA) positive in 70–90 % of generalized disease.
  • p‑ANCA (MPO‑ANCA) may be present in limited forms.
• Complete blood count (CBC) – may show anemia or leukocytosis.
• Renal panel – creatinine, BUN, electrolytes.
• Urinalysis – hematuria, red‑cell casts.
• Erythrocyte sedimentation rate (ESR) and C‑reactive protein (CRP) – markers of inflammation.

Imaging

• Chest X‑ray or CT scan: Detects nodules, cavitations, or infiltrates.
• Sinus CT: Shows mucosal thickening, bone destruction, or granulomas.
• Renal ultrasound: Evaluates kidney size; not diagnostic but helps assess chronic damage.

Biopsy (gold standard)

• Upper or lower respiratory tract tissue demonstrating necrotizing granulomatous inflammation with vasculitis.
• Kidney biopsy showing pauci‑immune crescentic glomerulonephritis.
• Skin or nerve biopsy can be used when organ‑specific sampling is not feasible.

Diagnostic criteria

Both the 1990 American College of Rheumatology (ACR) criteria and the 2022 ACR/EULAR Classification Criteria for GPA are used in clinical practice. A combination of ≥2 of the following typically confirms diagnosis:

1. Nasopharyngeal involvement (e.g., chronic sinusitis, nasal ulceration)
2. Chest imaging showing nodules or cavitary lesions
3. Kidney involvement with hematuria or red‑cell casts
4. Positive PR3‑ANCA (c‑ANCA) serology
5. Biopsy confirming necrotizing granulomatous vasculitis

Treatment Options

Therapy aims to induce remission quickly, then maintain disease control while minimizing drug toxicity. Treatment is usually coordinated by a rheumatologist, nephrologist, and pulmonologist.

Induction (remission‑inducing) therapy

• Glucocorticoids: High‑dose oral prednisone (1 mg/kg/day) or IV methylprednisolone (500‑1000 mg daily for 3 days) for severe disease.
• Cyclophosphamide: Oral (2 mg/kg/day) or IV pulse (15 mg/kg every 2–3 weeks) for 3–6 months. Historically the cornerstone for severe GPA.
• Rituximab: Anti‑CD20 monoclonal antibody (375 mg/m² weekly × 4 or 1 g on day 1 and day 15). Equivalent to cyclophosphamide for induction and preferred in patients desiring fertility preservation or with contraindications to alkylating agents (Raveendran et al., 2021).
• Plasma exchange (PLEX): Considered for rapidly progressive glomerulonephritis or life‑threatening pulmonary hemorrhage.

Maintenance therapy

• Aza­zathioprine: 2 mg/kg/day for 12–18 months after remission.
• Methotrexate: 15–25 mg weekly (if renal function permits); an alternative to azathioprine.
• Rituximab: 500 mg every 6 months for 2 years can be used for maintenance, especially after rituximab induction.
• Low‑dose glucocorticoids: Tapered gradually to ≤5 mg/day of prednisone by 6–12 months.

Adjunctive measures

• Prophylactic trimethoprim‑sulfamethoxazole (TMP‑SMX) to reduce risk of *S. aureus* sinus infection and opportunistic Pneumocystis jirovecii pneumonia.
• Vaccinations: pneumococcal, influenza, hepatitis B (before immunosuppression).
• Bone protection: calcium, vitamin D, and possibly bisphosphonates when chronic steroids are used.
• Fertility counseling and sperm banking for men, or oocyte preservation for women prior to cyclophosphamide.

Lifestyle and supportive care

• Smoking cessation – reduces respiratory complications.
• Regular monitoring of blood pressure, renal function, and complete blood counts.
• Physical therapy for musculoskeletal pain and fatigue.

Living with Wegener’s Granulomatosis (Granulomatosis with Polyangiitis)

Managing GPA is a long‑term partnership between the patient and healthcare team. Below are practical strategies to maintain quality of life.

Medication adherence

• Use a pill organizer and set alarms for daily doses.
• Keep a medication list and share it with every provider you see.
• Report side‑effects promptly—adjustments can prevent serious complications.

Monitoring and follow‑up

• Schedule rheumatology visits every 1–3 months during induction, then every 3–6 months for maintenance.
• Laboratory checks (CBC, CMP, ANCA titers) typically every 4–6 weeks initially, then spaced out.
• Urinalysis at each visit to detect early renal involvement.

Protecting organ function

• Renal: stay hydrated, avoid NSAIDs or nephrotoxic drugs, and monitor blood pressure.
• Pulmonary: perform regular breathing exercises; seek prompt evaluation of new cough or shortness of breath.
• Ophthalmic: annual eye exams if ocular involvement has been documented.

Managing fatigue and pain

• Prioritize sleep hygiene—aim for 7–9 hours/night.
• Low‑impact aerobic activity (walking, swimming) 3–5 times/week improves stamina.
• Mind‑body techniques (tai chi, meditation) can reduce stress‑related flare triggers.

Emotional health

• Consider counseling or support groups (e.g., Vasculitis Foundation). The psychological burden is significant; peer support can improve coping.
• Family education: ensure close relatives understand the disease, medication side‑effects, and when to call a doctor.

Travel and daily activities

• Carry a medical alert card stating “Granulomatosis with polyangiitis – on immunosuppressants”.
• Bring a short course of steroids for emergencies (e.g., sudden flares).
• Maintain up‑to‑date vaccinations before international travel.

Prevention

Because GPA’s exact cause is unknown, primary prevention is limited. However, several steps can lower the likelihood of flares or secondary complications:

• Avoid tobacco and silica exposure: Wear protective masks in dusty occupations.
• Prompt treatment of nasal *S. aureus* colonization: Regular ENT follow‑up and decolonization protocols where indicated.
• Vaccinations: Flu, COVID‑19, pneumococcal, and hepatitis B vaccines reduce infection‑related immune activation.
• Lifestyle: Balanced diet, regular exercise, and stress‑reduction techniques may decrease immune dysregulation.

Complications

If left untreated, GPA can cause irreversible organ damage. Even with therapy, certain complications remain possible.

Renal

• Progressive chronic kidney disease → end‑stage renal disease (ESRD) requiring dialysis or transplant.

Pulmonary

• Permanent cavitary lung lesions, scarring, or bronchiectasis.
• Life‑threatening alveolar hemorrhage.

ENT/ocular

• Permanent nasal septal perforation, saddle‑nose deformity.
• Vision loss from scleritis or orbital granulomas.

Cardiovascular

• Pericarditis, myocarditis, or accelerated atherosclerosis due to chronic inflammation.

Infection

• Immunosuppression increases susceptibility to bacterial, viral, and fungal infections.
• Reactivation of latent tuberculosis; screen before starting biologics.

Medication‑related

• Cyclophosphamide – bladder toxicity, infertility, secondary malignancies.
• Long‑term glucocorticoids – osteoporosis, diabetes, cataracts, hypertension.
• Rituximab – hypogammaglobulinemia, infusion reactions.

When to Seek Emergency Care

---

References: Mayo Clinic. Granulomatosis with polyangiitis (Wegener’s). 2022; CDC. Vasculitis surveillance. 2021; NIH. ANCA‑associated vasculitis guideline. 2023; Raveendran et al., “Rituximab versus cyclophosphamide for induction of remission in GPA”, *Ann Rheum Dis*, 2021; American College of Rheumatology/EULAR Classification Criteria for GPA, 2022; WHO. WHO Classification of Tumors (2020).

```